16.3 Reproductive Pathology & Hormone-Related Neoplasia
Key Takeaways
PCOS: insulin resistance and disordered gonadotropin drive → ovarian androgen excess, anovulation, unopposed estrogen (endometrial risk), polycystic morphology; treat metabolic drivers and cycle control.
Complete mole is usually 46,XX (paternal only) with diffuse villous swelling, no fetus, very high hCG; partial mole is often 69,XXY with fetal parts. Both are gestational trophoblastic disease; choriocarcinoma is invasive trophoblastic malignancy with high hCG.
Cervical cancer is driven by high-risk HPV E6/E7 (p53 and Rb inactivation); endometrial carcinoma type I is estrogen-related (hyperplasia pathway); ovarian tumors split surface epithelial, germ cell, and sex cord–stromal with marker patterns.
Breast cancer risk rises with cumulative estrogen exposure; receptors ER/PR/HER2 guide therapy. BPH is DHT-sensitive periurethral hyperplasia; prostate cancer is peripheral zone adenocarcinoma with PSA context and osteoblastic mets.
Testicular germ-cell tumors: seminoma (PLAP+, radiosensitive, homogeneous) vs nonseminoma (AFP/hCG patterns, more aggressive). Cryptorchidism raises germ-cell tumor and infertility risk.
16.3 Reproductive Pathology & Hormone-Related Neoplasia
Quick Answer: PCOS = androgen excess + anovulation + metabolic risk. Endometriosis = ectopic endometrium with cyclic pain/infertility. PID → tubal scarring → ectopic. Complete vs partial mole by karyotype and fetal tissue. HPV E6/E7 → cervical ca. Endometrial ca often estrogen-driven. Know ovarian/breast/prostate/testicular tumor buckets and markers.
This section converts physiology into disease packages. CBSE items often give a lab + morphology hint and ask for the mechanism (e.g., unopposed estrogen, HPV E7–Rb, DHT in BPH, cryptorchid germ-cell risk).
PCOS (Polycystic Ovary Syndrome)
Core pathophysiology (simplified, high-yield):
- Insulin resistance → hyperinsulinemia increases ovarian androgen production and lowers SHBG → higher free androgens.
- Altered GnRH/LH tone (often elevated LH:FSH ratio in classic teaching) supports theca androgen output.
- Androgens impair orderly folliculogenesis → chronic anovulation, oligomenorrhea, cystic follicles on ultrasound ("string of pearls"—supportive, not solely diagnostic).
- Anovulation → unopposed estrogen (no cyclic progesterone) → endometrial hyperplasia and endometrial carcinoma risk.
- Clinical: hirsutism, acne, obesity/central adiposity common, acanthosis nigricans with insulin resistance, infertility.
Differential anchors: Late-onset CAH (17-OHP), androgen-secreting tumors (rapid virilization, very high testosterone), Cushing, hyperprolactinemia, thyroid disease. Treatment themes: weight loss/exercise; combined OCPs for cycle control and SHBG rise; spironolactone for hirsutism; metformin in insulin resistance/diabetes risk; ovulation induction (letrozole/clomiphene) for fertility—exam focuses more on mechanism than regimens.
Endometriosis
Ectopic endometrial glands and stroma outside the uterus (ovaries → chocolate cysts/endometriomas, pelvic peritoneum, cul-de-sac, uterosacral ligaments). Estrogen-dependent, cyclic hemorrhage → inflammation, fibrosis, adhesions, pain (dysmenorrhea, dyspareunia), and infertility (anatomic + inflammatory).
Theories: retrograde menstruation (Sampson), coelomic metaplasia, lymphatic/vascular spread. Definitive diagnosis historically by laparoscopy; clinically recognized by symptom pattern. OCPs, progestins, GnRH agonists reduce stimulation; surgery for severe disease/fertility—again, mechanism > protocol on CBSE.
PID and Ectopic Pregnancy
Pelvic inflammatory disease usually follows ascending infection (N. gonorrhoeae, C. trachomatis, polymicrobial anaerobes). Tubal epithelial injury and ciliary damage → salpingitis, tubo-ovarian abscess risk, chronic scarring.
Ectopic pregnancy (most often tubal ampulla): fertilized ovum implants outside endometrium. Risk factors: prior PID/tubal surgery, prior ectopic, assisted reproduction, smoking, IUD in situ (pregnancy rare but if occurs, higher ectopic proportion). Presentation: amenorrhea, unilateral pain, spotting; rupture → acute abdomen and shock. hCG positive with empty uterus on ultrasound and/or inappropriate hCG rise. Pathophysiology link: impaired tubal transport from scarring.
Gestational Trophoblastic Disease
| Feature | Complete mole | Partial mole |
|---|---|---|
| Karyotype (classic) | 46,XX (usually all paternal; empty ovum + duplicated sperm) or 46,XY paternal | 69,XXY (or other triploid) maternal + paternal |
| Fetal tissue | Absent | Present (anomalous) |
| Villi | Diffuse hydropic swelling; trophoblastic hyperplasia marked | Focal hydropic change |
| hCG | Markedly elevated | Moderately elevated |
| Clinical | "Snowstorm" ultrasound, size > dates, hyperemesis, preeclampsia early, theca-lutein cysts | Less dramatic |
| Malignant risk | Higher risk of invasive mole / choriocarcinoma | Lower than complete |
Choriocarcinoma: malignant trophoblast, early hematogenous spread (lung, brain); very high hCG; responds to chemotherapy (methotrexate-based regimens historically classic). Monitor hCG after mole evacuation.
Cervical Cancer and HPV
High-risk HPV (16, 18 most tested) infects transformation zone epithelium. Viral E6 binds p53 → degradation; E7 binds Rb → frees E2F → cell cycle progression. Progression: koilocytes → CIN grades → invasive squamous cell carcinoma (or adenocarcinoma with certain types). Risk cofactors: smoking, immunosuppression, multiple partners, early coitarche, lack of screening.
Screening/prevention concept: Pap/HPV testing catches precursors; vaccination targets major oncogenic (and some low-risk wart) types. Local invasion to parametria/ureters can cause hydronephrosis—classic advanced disease death pathway in older vignettes.
Endometrial Hyperplasia and Carcinoma
Estrogen without adequate opposing progesterone drives endometrial proliferation: obesity (aromatization in fat), anovulation/PCOS, nulliparity, early menarche/late menopause, unopposed estrogen therapy, estrogen-secreting tumors (granulosa cell).
| Pathway | Features |
|---|---|
| Type I endometrioid | Hyperplasia → atypical hyperplasia → carcinoma; ER-positive; better prognosis; PTEN mutations often cited |
| Type II (e.g., serous) | Atrophic background, p53, older thin women, more aggressive |
Protective factors: combined OCPs, multiparity, progesterone exposure. Postmenopausal bleeding is carcinoma until adequately evaluated (exam heuristic).
Ovarian Tumors (High-Yield Taxonomy)
Surface epithelial (most common overall in adults)
- Serous: cystic, psammoma bodies possible; cystadenoma vs cystadenocarcinoma; most common malignant epithelial type.
- Mucinous: multiloculated, mucin; pseudomyxoma risk considerations (appendiceal primary often).
- Endometrioid: associated with endometriosis/endometrial carcinoma.
- Clear cell / Brenner: less common; Brenner has transitional-like epithelium, coffee-bean nuclei.
Risk: more ovulation (nulliparity), genetic (BRCA, Lynch); protective: OCPs, multiparity, breastfeeding (fewer lifetime ovulations).
Germ cell (younger patients)
| Tumor | Marker / pearl |
|---|---|
| Dysgerminoma | Male seminoma counterpart; LDH, PLAP; radiosensitive |
| Yolk sac (endodermal sinus) | AFP; Schiller-Duval bodies |
| Choriocarcinoma (ovarian) | hCG; cytotrophoblast + syncytiotrophoblast |
| Immature teratoma | Malignant germ cell; immature neuroepithelium graded |
| Mature cystic teratoma (dermoid) | Benign common; teeth/hair; struma ovarii (thyroid) can cause hyperthyroidism |
Sex cord–stromal
- Granulosa cell tumor: estrogen secretion → endometrial hyperplasia/bleeding; Call-Exner bodies; inhibin marker.
- Sertoli–Leydig: androgens → virilization; rare.
- Fibroma: Meigs syndrome (ovarian fibroma + ascites + pleural effusion).
Breast: Fibrocystic Change vs Cancer
Fibrocystic changes: common, hormone-related, cyclic pain/nodularity; blue-dome cysts; apocrine metaplasia; generally benign. Proliferative lesions with atypia raise risk more than nonproliferative fibrocystic change.
Breast carcinoma risk factors: age, female sex, family history/BRCA1/2, dense breasts, early menarche, late menopause, nulliparity, late first pregnancy, combined HRT, radiation, alcohol, obesity (postmenopausal aromatase).
| Receptor profile | Therapeutic implication (concept) |
|---|---|
| ER/PR positive | Hormonal therapy (tamoxifen SERM; aromatase inhibitors in postmenopausal) |
| HER2 amplified | HER2-targeted therapy (trastuzumab class) |
| Triple negative | More aggressive; chemo-based strategies; BRCA association |
Histology pearls: invasive ductal (most common); lobular (loss of E-cadherin, lines/Indian file); DCIS → microcalcifications on mammography; Paget disease of nipple (DCIS extends to epidermis).
BPH vs Prostate Cancer
| Feature | BPH | Prostate adenocarcinoma |
|---|---|---|
| Zone | Transitional / periurethral | Peripheral zone (often posterior—DRE nodule) |
| Driver | DHT-dependent hyperplasia | Multifactorial; androgens permissive |
| Symptoms | Obstructive/irritative voiding, smooth enlargement | May be asymptomatic early; nodule/induration |
| PSA | Can elevate modestly | Elevates; also free/total patterns, velocity—context required |
| Mets | Does not metastasize | Osteoblastic bone mets classic |
| Therapy theme | α1-blockers, 5α-reductase inhibitors | Surgery/radiation/androgen deprivation for advanced |
Testicular Tumors and Cryptorchidism
Cryptorchidism: failure of testicular descent; most resolve spontaneously early, but persistent undescended testes raise infertility (heat-sensitive spermatogenesis) and germ-cell tumor risk—including in the contralateral descended testis to some degree. Orchiopexy facilitates surveillance and may improve fertility potential; tumor risk not fully eliminated.
Germ-cell tumors (≈95% of testicular malignancies)
| Type | Features / markers |
|---|---|
| Seminoma | Homogeneous, fried-egg cells, PLAP, radiosensitive, better prognosis; hCG occasionally from syncytiotrophoblast elements |
| Embryonal carcinoma | Aggressive, hemorrhagic/necrotic; may raise AFP/hCG |
| Yolk sac | Children; AFP; Schiller-Duval |
| Choriocarcinoma | hCG very high; hematogenous spread early |
| Teratoma | All three germ layers; mature teratoma in post-pubertal males still considered malignant potential unlike mature ovarian dermoid |
| Mixed | Common; markers follow components |
Nonseminomatous GCT often produce AFP and/or hCG; management and prognosis differ from pure seminoma. Painless mass is the classic presentation; biopsy is not done pre-orchiectomy in standard teaching (spread risk)—orchiectomy is diagnostic/therapeutic.
Sex cord stromal tumors (Leydig cell: Reinke crystals, androgens/estrogens; Sertoli cell) are less common.
Closing Integration Map
- Anovulation + unopposed estrogen → PCOS and type I endometrial cancer risk share a pathway.
- HPV E6/E7 is the molecular sentence for cervical neoplasia.
- Mole karyotype table separates complete vs partial before you guess hCG magnitude.
- Zone anatomy separates BPH (transition) from prostate cancer (peripheral).
- Markers (hCG, AFP, PLAP, inhibin, ER/PR/HER2) are the fastest way to score tumor questions.
- Cryptorchidism links pediatric anatomy to adult oncology and infertility physiology from 16.1.
A 24-year-old woman has oligomenorrhea, hirsutism, and BMI 34. LH is relatively high compared with FSH; fasting insulin is elevated. Which mechanism best explains her increased risk of endometrial carcinoma?
Excess luteal progesterone causing secretory exhaustion of glands
Chronic anovulation with unopposed estrogen stimulation of the endometrium
Direct insulin binding to endometrial progesterone receptors blocking proliferation
HPV E6-mediated p53 degradation in endometrial epithelium
Ultrasound after missed abortion shows a "snowstorm" uterus without a fetus. Karyotype of evacuated tissue is 46,XX of paternal origin only. Which diagnosis is most accurate?
Partial hydatidiform mole (triploid, fetal parts present)
Placental site trophoblastic tumor with low hCG
Complete hydatidiform mole
Normal dizygotic twin gestation with vanishing twin
A 30-year-old man has a painless testicular mass. Histology shows sheets of large cells with clear cytoplasm and central nuclei; PLAP is positive; AFP is normal; hCG is minimally elevated. Which tumor type is most likely?
Yolk sac tumor
Pure choriocarcinoma
Leydig cell tumor with Reinke crystals as the defining feature
Seminoma
Sections you finish are checked off in the contents.